{"summary":"Executive with experience in oncology\/immuno-oncology drug discovery and development, cell therapy, in vitro diagnostics, and biologic drug CMC development. ","lastName":"Setiady","objectUrn":"urn:li:member:81340162","geoRegion":"Lexington, Massachusetts, United States","fullName":"Yulius Setiady","firstName":"Yulius","currentPositions":[{"companyName":"PT Kalbe Farma, Tbk","description":"Coordinate and streamline R&D related activities in biopharma, pharma, nutrition, and consumer health.","title":"Head of Corporate R&D","companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"geographicArea":"DKI Jakarta","country":"Indonesia","city":"Jakarta","postalCode":"10510","line2":"Jl. Letjen Suprapto Kav 4","line1":"KALBE Building"},"website":"http:\/\/www.kalbe.co.id\/","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/pt-kalbe-farma\/","industry":"Pharmaceutical Manufacturing"},"companyUrn":"urn:li:fs_salesCompany:154673","tenureAtCompany":{"numYears":1,"numMonths":5},"startedOn":{"month":1,"year":2023}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAATZJwIBk1tMsAMnNdUVMsXdl3G2VWzA2jk,NAME_SEARCH,LQmQ)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1715367683835?e=1723075200&v=beta&t=6Vx7DmYZFJ-3nddqKWz9Kbb57wu6-7Xsj-XxqqEYpgk","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1715367683835?e=1723075200&v=beta&t=ZXQgm_-bzdRRCVOmH868Wu-LXOpAkLQG1KeZZGL-eCY","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1715367683835?e=1723075200&v=beta&t=NNwFI7-KlN-BhK6kiD-xoCxwKWILtqOSjuPHBWGdmGk","height":400},{"width":651,"fileIdentifyingUrlPathSegment":"800_800\/0\/1715367683835?e=1723075200&v=beta&t=COAFkIIwaPLcDWm2LJuOwZpK8LCmC-O_WD6PTQzBycY","height":651}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D4E03AQF50RkNxsOqlQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"degree":"Doctor of Philosophy (PhD)","schoolUrn":"urn:li:fs_salesSchool:15115000","eduId":245114066,"school":"urn:li:fs_salesSchool:15115000","fieldsOfStudy":["Molecular Biology"],"schoolName":"Osaka University"},{"degree":"Master of Engineering - MEng","schoolUrn":"urn:li:fs_salesSchool:15115000","eduId":684438624,"school":"urn:li:fs_salesSchool:15115000","fieldsOfStudy":["Molecular Biology"],"schoolName":"Osaka University"},{"degree":"Bachelor of Engineering - BE","schoolUrn":"urn:li:fs_salesSchool:15115000","eduId":684435952,"school":"urn:li:fs_salesSchool:15115000","fieldsOfStudy":["Biophysics"],"schoolName":"Osaka University"}],"skills":[{"numOfEndorsement":7,"name":"Drug Development"},{"numOfEndorsement":9,"name":"Antibodies"},{"numOfEndorsement":5,"name":"Drug Discovery"},{"numOfEndorsement":8,"name":"Cell Culture"},{"numOfEndorsement":6,"name":"Biochemistry"},{"numOfEndorsement":3,"name":"Molecular Biology"},{"numOfEndorsement":3,"name":"Biopharmaceuticals"},{"numOfEndorsement":5,"name":"Cell Biology"},{"numOfEndorsement":5,"name":"Life Sciences"},{"numOfEndorsement":4,"name":"Protein Chemistry"},{"numOfEndorsement":2,"name":"Autoimmunity"},{"numOfEndorsement":2,"name":"pharmacology"},{"numOfEndorsement":3,"name":"Team Building"},{"numOfEndorsement":2,"name":"Flexible Approach"},{"numOfEndorsement":3,"name":"active listening"},{"numOfEndorsement":3,"name":"effective communication"},{"numOfEndorsement":4,"name":"Creative Problem Solving"},{"numOfEndorsement":4,"name":"Strategic Thinking"},{"numOfEndorsement":3,"name":"Team Motivation"},{"numOfEndorsement":2,"name":"Cross-functional Team Leadership"},{"numOfEndorsement":3,"name":"Constructive Feedback"},{"numOfEndorsement":3,"name":"Critical Thinking"},{"numOfEndorsement":4,"name":"Immunology"},{"numOfEndorsement":1,"name":"ELISA"},{"numOfEndorsement":8,"name":"Assay Development"},{"numOfEndorsement":4,"name":"Pharmaceutical Industry"},{"numOfEndorsement":11,"name":"Biotechnology"},{"numOfEndorsement":3,"name":"Oncology"},{"numOfEndorsement":2,"name":"Multi-color Flow Cytometry"},{"numOfEndorsement":1,"name":"Primary Cell Isolation"},{"numOfEndorsement":1,"name":"Immunohistochemistry"}],"numOfConnections":678,"patents":[],"headline":"Kalbe","courses":[],"certifications":[],"memberBadges":{"premium":false,"openLink":false,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/yulius-setiady-a2a2a723","organizations":[],"location":"Lexington, Massachusetts, United States","publications":[],"positions":null,"posts":[{"createdAt":1715146140000,"insightId":"b225a136-7140-4bc4-928e-4f4bcb67064d","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":40},{"type":"PRAISE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7193844485682835456","threadUrn":"urn:li:activity:7193844485682835456","reactionsCount":42,"commentsCount":1,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193844485238185984","message":{"attributes":[],"text":"Proud to be part of the team that develops this drug. Next step is to get it approved in EU for patients in dialysis."},"rootActivity":{"contentSummaryUnion":{"mediaContentSummary":{"mediaType":"STILLIMAGE","thumnailUrl":"https:\/\/media.licdn.com\/dms\/image\/D5622AQGIWa2XxXFecw\/feedshare-shrink_2048_1536\/0\/1715077498220?e=1720051200&v=beta&t=tkrCSikgFB_80i9A4CTgVfrTIw-M3T7F3Q8QM8fYEkU"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193556412717756416","message":{"attributes":[{"length":9,"start":1281,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:onekalbe"}}},{"length":6,"start":1291,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:kalbe"}}},{"length":22,"start":1298,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:bersamasehatkanbangsa"}}},{"length":14,"start":1321,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:efepoetinalfa"}}},{"length":13,"start":1336,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:ginjalkronis"}}},{"length":7,"start":1350,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:anemia"}}},{"length":10,"start":1358,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:kalbenews"}}}],"text":"Kalbe Farma melalui anak usaha PT Kalbe Genexine Biologics (KGbio) dan PT Finusolprima Farma Internasional (FIMA) meluncurkan Efepoetin Alfa, obat baru untuk terapi anemia pada pasien ginjal kronik. Obat ini merupakan inovasi karya anak bangsa dan menjadi yang pertama di Indonesia! Peluncuran obat ini merupakan kelanjutan langkah Kalbe dan anak usahanya setelah mendapatkan izin edar dari Badan Pengawas Obat dan Makanan RI (Badan POM) pada Oktober 2023 lalu. \n\nKeamanan dan efikasi Efepoetin Alfa telah dibuktikan melalui uji klinis global yang dilakukan di Indonesia, Australia, Taiwan, Thailand, Malaysia, Filipina, dan Korea Selatan. Uji klinis ini melibatkan 391 pasien penyakit ginjal kronik predialisis dan menunjukkan bahwa Efepoetin Alfa efektif dalam memperbaiki, mempertahankan, dan menstabilkan kadar hemoglobin, serta memberikan toleransi yang baik saat dibandingkan dengan Methoxy Polyethylene Glycol-Epoetin Beta. Efepoetin Alfa bekerja dengan merangsang produksi sel darah merah, sehingga membantu tubuh pasien ginjal kronik yang mengalami anemia. Obat ini terbukti efektif, aman, dan nyaman digunakan, dengan suntikan hanya 1-2 kali sebulan.\n\nEfepoetin Alfa merupakan bukti dedikasi Kalbe dalam menghadirkan solusi kesehatan inovatif bagi masyarakat Indonesia.\n\n#onekalbe #kalbe #bersamasehatkanbangsa #EfepoetinAlfa #ginjalkronis #anemia #KalbeNews"},"entityUrn":"urn:li:share:7193556412717756416"},"entityUrn":"urn:li:share:7193844485238185984"}}},{"createdAt":1715147040000,"insightId":"c3935895-f023-4f1c-b84d-231d3f6c1b20","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7193797295631396864,7193848310661595136)","threadUrn":"urn:li:ugcPost:7193797295631396864","reactionsCount":4,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congrats to KGBio and Kalbio team for the success of bringing the first  Indonesian novel biologic drug to the market. A shout-out to Genexine team that discover the molecule and codevelop it with us. I am proud to be part of the team. Let's strive to get this drug approved in EU for CKD patients in dialysis."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7193797295631396864"}}},{"createdAt":1715146140000,"insightId":"2e910f50-89dc-43c3-83a2-1dbe03188c7c","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":4}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(activity:7193556414194204672,7193844410902532097)","threadUrn":"urn:li:activity:7193556414194204672","reactionsCount":4,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Proud to be part of the team that develops this drug. Next step is to get it approved in EU for patients in dialysis."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:activity:7193556414194204672"}}}]}